Yarrow Bioscience, Inc. (VYNE) Form 424B5 — Sep 11, 2026
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics; metadata ticker VYNE, now trading on Nasdaq as YARW) filed a preliminary prospectus supplement on Form 424B5 for a follow-on offering of common stock, with pre-funded warrants exercisable at $0.0001 per share available in lieu of shares to certain investors. Public offering price, share counts and estimated net proceeds are left blank pending completion of the offering. Jefferies, TD Cowen and Guggenheim Securities are joint book-running managers with LifeSci Capital as lead manager; the underwriters hold a 30-day option for additional shares and the company, its officers and directors are locked up for 60 days.
Key figures
- Cash Position
- 108800000
- Runway
- into 2030, including completion of Phase 2b Graves' disease trial
- Atm capacity
- 50000000
- Shelf capacity
- 250000000
- Cash june 30 2026
- 18700000
- Cash estimate date
- August 31, 2026 (preliminary, unaudited management estimate)
- Lockup period days
- 60
- Options outstanding
- 2002282
- Reverse split ratio
- 1-for-50 (effected July 24, 2026)
- Atm shares sold to date
- 0
- Pro forma ntbv per share
- 39.92
- Closing price aug 12 2026
- 42.77
- Last sale price sept 9 2026
- 29.11
- Pro forma shares outstanding
- 2803078
- Pre funded warrant exercise price
- 0.0001
- Pro forma net tangible book value
- 111900000
- Options weighted avg exercise price
- 6.19
- Pre funded warrants outstanding shares
- 25781240
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.